查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701375

糖尿病足潰瘍生技藥品市場規模、佔有率、趨勢分析報告：按產品、適應症、最終用途、地區和細分市場預測，2025 年至 2030 年

Diabetic Foot Ulcer Biologics Market Size, Share & Trends Analysis Report By Product, By Indication, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10個工作天內

價格

糖尿病足潰瘍生技藥品市場的成長與趨勢

根據 Grand View Research, Inc. 的最新報告，全球糖尿病足潰瘍生技藥品市場規模預計到 2030 年將達到 31.1 億美元，2025 年至 2030 年的複合年成長率為 7.9%。

這種成長是由市場參與企業之間日益激烈的競爭、研究活動的活性化以及人口老化導致的臨床測試和研究的增加所推動的。此外，工業公司擴大影響力的重點也有望在未來幾年推動市場成長。

例如，美國國家醫學圖書館於 2022 年 8 月發表的一項研究報告稱，糖尿病足潰瘍 (DFU) 的風險會隨著年齡的成長而增加。這種相關性與糖尿病病程較長、高血糖的累積效應以及微血管和大血管併發症的盛行率較高密切相關。因此，老年人口的增加預計會導致糖尿病足潰瘍的增加。根據世界衛生組織2024年10月發布的資料，預計未來幾年老年人口數將大幅增加。以下是世界衛生組織的預測：

  • 到2030年，全球每六人中就有一人年齡超過60歲，從2020年的10億增加到14億。
  • 到2050年，全球60歲以上人口預計將加倍，達到21億人。
  • 預計2020年至2050年間，80歲以上人口將增加兩倍，達4.26億。

此外，預計在預測期內，多家公司將開始開發糖尿病足潰瘍的創新治療方法，臨床試驗的數量也將不斷增加，這也將推動市場的發展。各行業參與者都積極參與臨床試驗，以帶來新型生技藥品。例如，2025年1月，臨床階段再生醫學公司RION宣布完成其精製外泌體製劑（PEP）治療糖尿病足潰瘍（DFU）的2期臨床試驗的患者招募。這項前瞻性、多中心、開放標籤研究旨在招募美國 59 名患者，並評估與標準傷口護理同時應用局部PEP 的安全性和有效性。 PEP 是一種源自人類血小板的專有凍乾粉，其中含有穩定的再生外泌體。外泌體旨在透過促進細胞增殖和減少發炎來增強人體的自然癒合過程，同時保護脆弱的組織，這是成功創傷治療的重要組成部分。

糖尿病足潰瘍生技藥品市場報告重點

  • 根據產品，2024 年糖尿病足潰瘍生技藥品市場在全球市場中以皮膚替代品部分為主。另一方面，組織工程產品領域預計未來幾年將實現最快成長。
  • 按適應症分類，神經缺血性潰瘍領域在 2024 年佔據市場最大收益佔有率，約 53.17%。相較之下，缺血性糖尿病足潰瘍領域預計在預測期內以最快的複合年成長率成長。
  • 根據最終用途，醫院部門佔據市場主導地位，2024 年的收益佔有率為 51.52%。然而，門診手術中心部門預計在預測期內將以最快的速度成長。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 糖尿病足潰瘍生技藥品市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 糖尿病足潰瘍生技藥品市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析

第4章糖尿病足潰瘍生技藥品市場：產品評估與趨勢分析

  • 細分儀表板
  • 全球糖尿病足潰瘍生技藥品市場的波動
  • 全球糖尿病足潰瘍生技藥品市場規模及趨勢分析（按產品分類）（2018-2030）
    • 皮膚替代品
    • 生長因子
    • 組織工程產品

第5章糖尿病足潰瘍生技藥品市場：適應症預測及趨勢分析

  • 細分儀表板
  • 全球糖尿病足潰瘍生技藥品市場的波動
  • 2018-2030年全球糖尿病足潰瘍生技藥品市場規模及趨勢分析（依適應症）
    • 神經缺血性潰瘍
    • 神經病變糖尿病足潰瘍
    • 缺血性糖尿病足潰瘍

6. 糖尿病足潰瘍生技藥品市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 全球糖尿病足潰瘍生技藥品市場的波動
  • 2018-2030年全球糖尿病足潰瘍生技藥品市場規模及趨勢分析（依最終用途）
  • 醫院
  • 診所
  • 門診手術中心（ASC）
  • 長期照護機構
  • 其他

7. 糖尿病足潰瘍生技藥品市場（按地區）、預測與趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測與趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 2024年主要企業市場佔有率分析
    • Organogenesis Holdings Inc.
    • Tissue Regenix
    • BioTissue
    • Integra LifeSciences
    • MIMEDX Group, Inc.
    • Convatec Inc.
    • Coloplast Group（Kerecis）
    • Biocomposites
    • Smith+Nephew, Inc.
    • Stedical Scientific, Inc.
    • Zimmer Biomet
    • GUNZE LIMITED
  • 熱圖分析/企業市場分析
  • 2024年企業市場佔有率預測分析
  • 其他主要市場參與企業
Product Code: GVR-4-68040-543-1

Diabetic Foot Ulcer Biologics Market Growth & Trends:

The global diabetic foot ulcer biologics market size is anticipated to reach USD 3.11 billion by 2030 and is projected to grow at a CAGR of 7.9% from 2025 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the growing competition among the market participants, rising research activities, the increasing number of clinical trials and studies along with increasing geriatric population. Moreover, the rising focus of industry players on expanding their presence is anticipated to propel market growth in the coming years.

For instance, a study from the National Library of Medicine in August 2022 reported that the risk of DFU increases with age. This correlation is closely linked to the longer duration of diabetes, the cumulative effects of hyperglycemia, and a higher prevalence of micro- and macrovascular complications. Therefore, the increasing prevalence of the geriatric population is expected to lead to a rise in diabetic foot ulcers. According to data published by the WHO in October 2024, the number of older people is estimated to increase significantly in the coming years. Below are some projections given by the WHO:

  • By 2030, 1 in 6 people worldwide will be aged 60 or older, with the population in this age group growing from 1 billion in 2020 to 1.4 billion.
  • By 2050, the worldwide population of individuals aged 60 and above is estimated to double, reaching 2.1 billion.
  • The number of people aged 80 or older is expected to triple from 2020 to 2050, reaching 426 million.

The increasing number of clinical trials is also expected to drive the market during the forecast period, attracting several companies to develop innovative treatments for diabetic foot ulcers. Various industry participants are actively engaged in clinical studies to bring novel biologics in the industry. For instance, in January 2025, RION, a clinical-stage regenerative medicine company, announced the completion of patient enrollment for its Phase 2 clinical trial of the Purified Exosome Product (PEP) in treating diabetic foot ulcers (DFUs). This prospective, multicenter, open-label study enrolled 59 patients across the U.S. It aims to assess the safety and efficacy of PEP when applied topically alongside standard wound care. PEP is a proprietary, lyophilized powder derived from human platelets that contains stabilized regenerative exosomes. These exosomes are engineered to enhance the body's natural healing processes by promoting cellular growth and reducing inflammation while also protecting vulnerable tissues-crucial elements for successful wound healing.

Diabetic Foot Ulcer Biologics Market Report Highlights:

  • Based on product, the skin substitutes segment dominated the global diabetic foot ulcer biologics market in 2024. On the other hand, the tissue-engineered products segment is anticipated to grow at the fastest in the coming years.
  • Based on indication, the neuro-ischemic ulcers segment held the largest revenue share of around 53.17% in the market in 2024. In contrast, the ischemic diabetic foot ulcer segment is expected to grow the fastest CAGR over the forecast period.
  • Based on end use, the hospital segment dominated the market and accounted for a revenue share of 51.52% in 2024. On the other hand, ambulatory surgical centers segment is expected to grow the fastest over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Third Party Perspective
    • 1.3.5. Primary research
    • 1.3.6. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Data Sources
  • 1.8. List of Primary Sources
  • 1.9. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Foot Ulcer Biologics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of diabetic foot ulcer
      • 3.2.1.2. Technological advancements in biologics
      • 3.2.1.3. Rising geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of biologics products
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Rising distribution agreement for biologics
      • 3.2.3.2. Growing number of clinical trials
      • 3.2.3.3. Expansion of manufacturing and distribution facilities
      • 3.2.3.4. Expansion in emerging markets
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Intense Competition
  • 3.3. Diabetic Foot Ulcer Biologics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape

Chapter 4. Diabetic Foot Ulcer Biologics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
  • 4.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
    • 4.3.1. Skin Substitutes
      • 4.3.1.1. Skin-Substitutes market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.2. Biological
        • 4.3.1.2.1. Biological market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.3. Synthetic
        • 4.3.1.3.1. Synthetic market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.4. Bio-Synthetic
        • 4.3.1.4.1. Bio-Synthetic market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.2. Growth Factors
      • 4.3.2.1. Growth factors market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.3. Tissue-Engineered Products
      • 4.3.3.1. Tissue-engineered products market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Diabetic Foot Ulcer Biologics Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
  • 5.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 5.3.1. Neuro-ischemic Ulcers
      • 5.3.1.1. Neuro-ischemic ulcers market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.2. Neuropathic Diabetic Foot Ulcer
      • 5.3.2.1. Neuropathic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.3. Ischemic Diabetic Foot Ulcer
      • 5.3.3.1. Ischemic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Diabetic Foot Ulcer Biologics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
  • 6.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5. Clinics
    • 6.5.1. Clinics market estimates and forecast 2018 to 2030 (USD Million)
  • 6.6. Ambulatory Surgical Centers (ASCs)
    • 6.6.1. Ambulatory Surgical Centers (ASCs) market estimates and forecast 2018 to 2030 (USD Million)
  • 6.7. Long-Term Care Settings
    • 6.7.1. Long-term care settings market estimates and forecast 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Diabetic Foot Ulcer Biologics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. Reimbursement scenario
      • 7.3.2.5. U.S. market estimates and forecasts, 2018 - 2030
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Reimbursement scenario
      • 7.3.3.5. Canada market estimates and forecasts, 2018 - 2030
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Reimbursement scenario
      • 7.3.4.5. Mexico market estimates and forecasts, 2018 - 2030
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Competitive scenario
      • 7.4.1.3. Regulatory framework
      • 7.4.1.4. Reimbursement scenario
      • 7.4.1.5. UK market estimates and forecasts, 2018 - 2030
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Reimbursement scenario
      • 7.4.2.5. Germany market estimates and forecasts, 2018 - 2030
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Reimbursement scenario
      • 7.4.3.5. France market estimates and forecasts, 2018 - 2030
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Reimbursement scenario
      • 7.4.4.5. Italy market estimates and forecasts, 2018 - 2030
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Reimbursement scenario
      • 7.4.5.5. Spain market estimates and forecasts, 2018 - 2030
    • 7.4.6. Denmark
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Reimbursement scenario
      • 7.4.6.5. Denmark market estimates and forecasts, 2018 - 2030
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Reimbursement scenario
      • 7.4.7.5. Sweden market estimates and forecasts, 2018 - 2030
    • 7.4.8. Norway
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Reimbursement scenario
      • 7.4.8.5. Norway market estimates and forecasts, 2018 - 2030
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Reimbursement scenario
      • 7.5.1.5. Japan market estimates and forecasts, 2018 - 2030
    • 7.5.2. India
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. India market estimates and forecasts, 2018 - 2030
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. China market estimates and forecasts, 2018 - 2030
    • 7.5.4. South Korea
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. South Korea market estimates and forecasts, 2018 - 2030
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Reimbursement scenario
      • 7.5.5.5. Australia market estimates and forecasts, 2018 - 2030
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Reimbursement scenario
      • 7.5.6.5. Thailand market estimates and forecasts, 2018 - 2030
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Reimbursement scenario
      • 7.6.1.5. Brazil market estimates and forecasts, 2018 - 2030
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Argentina market estimates and forecasts, 2018 - 2030
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement scenario
      • 7.7.1.5. South Africa market estimates and forecasts, 2018 - 2030
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. UAE market estimates and forecasts, 2018 - 2030
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Organogenesis Holdings Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Tissue Regenix
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. BioTissue
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Integra LifeSciences
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. MIMEDX Group, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Convatec Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Coloplast Group (Kerecis)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Biocomposites
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Smith+Nephew, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Stedical Scientific, Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Zimmer Biomet
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GUNZE LIMITED
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
  • 8.4. Heat Map Analysis/ Company Market Position Analysis
  • 8.5. Estimated Company Market Share Analysis, 2024
  • 8.6. List of Other Key Market Players

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviation
  • Table 3. North America diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 4. North America diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 5. North America diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 6. North America diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 7. U.S. diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 8. U.S. diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 9. U.S. diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 10. Canada diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 11. Canada diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 12. Canada diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 13. Mexico diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 14. Mexico diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 15. Mexico diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 16. Europe diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 17. Europe diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 18. Europe diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 19. Europe diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 20. UK diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 21. UK diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 22. UK diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 23. Germany diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 24. Germany diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 25. Germany diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 26. France diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 27. France diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 28. France diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 29. Italy diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 30. Italy diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 31. Italy diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 32. Spain diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 33. Spain diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 34. Spain diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 35. Denmark diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 36. Denmark diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 37. Denmark diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 38. Sweden diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 39. Sweden diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 40. Sweden diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 41. Norway diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 42. Norway diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 43. Norway diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 48. China diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 49. China diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 50. China diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 51. Japan diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 52. Japan diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 53. Japan diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 54. India diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 55. India diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 56. India diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 57. South Korea diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 58. South Korea diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 59. South Korea diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 60. Australia diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 61. Australia diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 62. Australia diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 63. Thailand diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 64. Thailand diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 65. Thailand diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 66. Latin America diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 67. Latin America diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 68. Latin America diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 69. Latin America diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 70. Brazil diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 71. Brazil diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 72. Brazil diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 73. Mexico diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 74. Mexico diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 75. Mexico diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 76. Argentina diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 77. Argentina diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 78. Argentina diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 79. Middle East & Africa diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 83. South Africa diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 84. South Africa diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 85. South Africa diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 86. Saudi Arabia diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 89. UAE diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 90. UAE diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 91. UAE diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 92. Kuwait diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 93. Kuwait diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 94. Kuwait diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Diabetic Foot Ulcer Biologics Market, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 Market Opportunity Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 Global Diabetic Foot Ulcer Biologics Market, for Product, 2018 - 2030 (USD Million)
  • Fig. 15 Global Diabetic Foot Ulcer Biologics Market, for Skin Substitutes, 2018 - 2030 (USD Million)
  • Fig. 16 Global Diabetic Foot Ulcer Biologics Market, for Biological, 2018 - 2030 (USD Million)
  • Fig. 17 Global Diabetic Foot Ulcer Biologics Market, for Synthetic, 2018 - 2030 (USD Million)
  • Fig. 18 Global Diabetic Foot Ulcer Biologics Market, for Bio-Synthetic, 2018 - 2030 (USD Million)
  • Fig. 19 Global Diabetic Foot Ulcer Biologics Market, for Growth Factors, 2018 - 2030 (USD Million)
  • Fig. 20 Global Diabetic Foot Ulcer Biologics Market, for Tissue-Engineered Products, 2018 - 2030 (USD Million)
  • Fig. 21 Global Diabetic Foot Ulcer Biologics Market, for Indication, 2018 - 2030 (USD Million)
  • Fig. 22 Global Diabetic Foot Ulcer Biologics Market, for Neuro-ischemic Ulcers, 2018 - 2030 (USD Million)
  • Fig. 23 Global Diabetic Foot Ulcer Biologics Market, for Neuropathic Diabetic Foot Ulcer, 2018 - 2030 (USD Million)
  • Fig. 24 Global Diabetic Foot Ulcer Biologics Market, for Ischemic Diabetic Foot Ulcer, 2018 - 2030 (USD Million)
  • Fig. 25 Global Diabetic Foot Ulcer Biologics Market, for End Use, 2018 - 2030 (USD Million)
  • Fig. 26 Global Diabetic Foot Ulcer Biologics Market, for Hospitals, 2018 - 2030 (USD Million)
  • Fig. 27 Global Diabetic Foot Ulcer Biologics Market, for Clinics, 2018 - 2030 (USD Million)
  • Fig. 28 Global Diabetic Foot Ulcer Biologics Market, for Ambulatory Surgical Centers (ASCs), 2018 - 2030 (USD Million)
  • Fig. 29 Global Diabetic Foot Ulcer Biologics Market, for Long-Term Care Settings, 2018 - 2030 (USD Million)
  • Fig. 30 Global Diabetic Foot Ulcer Biologics Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Outlook, 2024 & 2030
  • Fig. 32 North America Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 47 China Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 48 India Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)